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Abstract
Background: Recruitment of stem cells to sites of tissue injury constitutes an important mechanism aimed at tissue
repair and regeneration. However, it is not clear how the diabetic milieu affects the viability of endogenous stem
cells. Thus, we tested the hypothesis that diabetes mellitus is associated with increased apoptosis which, in turn,
contributes to reduction in stem cells and the manifestation of type 2 diabetic nephropathy.
Methods: Sixteen-week-old male obese type 2 diabetic db/db mice, and their appropriate controls, were used for
assessment of the status of endothelial progenitor cells (EPCs), mesenchymal stem cells (MSCs), and hematopoetic
stem cells (HSCs) in the peripheral blood and renal tissue using specific cell markers. Further, we explored whether
diabetic animals display greater apoptosis of stem cell subsets.
Results: The peripheral blood cells of db/db mice displayed reduction in EPCs (p < 0.05) compared to those of
db/m controls. Further, kidney cells prepared from experimental groups also showed reductions in EPCs, MSCs, and
HSCs. We also observed increased apoptosis of stem cell subsets in cells prepared from kidneys of db/db than
those of db/m mice.
Conclusions: The present study shows a similar pattern of decline in stem cell subsets in peripheral blood and
kidneys of db/db mice, an effect likely related to increased apoptosis. Collectively, the results suggest that apoptosis
of stem cells likely contributes to eventual manifestation of renal failure in diabetes mellitus. Monitoring of blood
levels of stem cell subsets could predict failure of their reparative and protective effects and eventual
manifestations of diabetic complications.
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Background
The worldwide epidemic of diabetes mellitus, and asso-
ciated micro- and macro-angiopathic complications, is
one of the most pressing health-related challenges of our
time. Nephropathy is a major complication of diabetes
mellitus with a prevalence of 25–40 % [1]. Diabetic ne-
phropathy is characterized as glomerular and tubular
dysfunctions and variable increase in urinary albumin
excretion. The hallmark feature of diabetic nephropathy
is the decline in the glomerular filtration rate which
ultimately leads to end-stage renal disease (ESRD)
thereby requiring renal replacement therapy [2, 3]. In-
deed, 44 % of new cases of ESRD in the USA are caused
by diabetic nephropathy [1, 4].
The American Diabetes Association considers strict
glycemic control as the first-line intervention for the
prevention of diabetic complications [2, 5]. While strict
glycemic control delays the onset of diabetic nephropa-
thy, it does not completely prevent its progression.
Other intervention modalities include control of blood
pressure and use of pharmacological agents targeting the
renin-angiotensin-aldosterone axis. Nonetheless, clinical
trials do not suggest that such intervention modalities
prevent progression to ESRD [2, 6]. This suggests not
only the inadequacy of current drug therapies but also
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the failure of endogenous protective and reparative
mechanisms. This recognition has led to exploration of
the potential usefulness of stem cells in beneficially in-
fluencing the course of diabetic complications.
The beneficial effects of bone marrow-derived stem
cells and cord blood stems cells in the non-diabetic
obese mouse (an animal model of type 1 diabetes melli-
tus) have been established. The rationale for the use of
stem cells (e.g., in type 1 diabetes), in part, relates to
their immunoregulatory properties and promotion of
peripheral tolerance to pancreatic β cells [7]. Import-
antly, hematopoietic stem cells rescue peripheral toler-
ance towards pancreatic β cells in type 1 diabetic
subjects raising the prospect for a stem cell-based treat-
ment regimen to prevent or delay the development of
chronic complications of the disease [8].
With respect to the kidney, in the streptozotocin-
induced type 1 diabetic mice, mesenchymal stem cell
(MSC) administration ameliorated histopathological fea-
tures including fibrosis, glomerulosclerosis, glomerular
basement thickening, capillary occlusion, reduced podo-
cyte density, and effacement of foot processes. Authors
concluded that, despite persistence of dysglycemia, MSC
administration exerts renoprotection likely via the pro-
motion of a pro-regenerative microenvironment [9]. Al-
though the role of inflammation in type 2 diabetic
nephropathy is increasingly appreciated [10], there is a
relative lack of information regarding the usefulness of
stem cells in this condition.
The beneficial effects of stem cells in tissue repair and
regeneration are related primarily to the release of sol-
uble factors which, in turn, curtail the inflammatory re-
sponse to tissue injury. Importantly, however, the
diabetic milieu exerts detrimental effects on the number
and function of stem cells [11–15]. Given that the vast
majority of diabetic patients have type 2 diabetes and
type 2 diabetic nephropathy is the leading cause of end-
stage renal diseases, it is essential to unravel the impact
of diabetic milieu on stem cells in this disease condition.
Thus, the present study was intended to explore the sta-
tus of components of stem cells in the setting of type 2
diabetic nephropathy. Accordingly, we tested the hy-
pothesis that apoptosis of stem cells contributes to im-
paired reparative/regenerative capacity in type 2 diabetic
nephropathy. Ultimately, a more comprehensive dy-
namic and mechanistic understanding is needed com-
bining experimental data with computational modeling
so that a targeted therapeutic approach can be possible.
Methods
Male db/m and db/db mice (n = 5/group) were pur-
chased from the Jackson Laboratories and housed, with
free access to food and fluid, in the laboratory animal fa-
cilities at Augusta University. The use of animals for
these studies conformed to the institutional guidelines
for the care and use of laboratory animals.
We have shown that hallmark features of db/db mice,
compared to their lean controls, include (a) a significant
increase in body weight, (b) a significant increase in
homeostatic model assessment index, a measure of insu-
lin resistance, (c) a significant increase in hemoglobin
A1c, an index of chronic glycemic control, (d) a signifi-
cant increase in albumin excretion but reduction in cre-
atinine clearance, and (e) histopathological changes
including mesangial expansion and glomerular sclerosis
[16, 17]. Starting at about 8 weeks of age, these features
become progressively more prominent, and by about
16 weeks of age, these hallmark features are fully mani-
fested [16]. Given its hallmark features, the db/db mouse
is a very relevant animal model of type 2 diabetic
nephropathy.
At 16 weeks of age, db/db and db/m mice were sacri-
ficed and blood samples were obtained for determination
of peripheral blood stem cell subsets. Also, the kidneys
were procured for the preparation of renal cells and as-
sessment of subsets of stem cells and apoptosis. In
addition, cytospins were prepared using renal cell prepa-
rations for subsequent immunofluorescent assessment
of caspase 3-positive stem cell subsets. Identification of
stem cell subsets was based on the use of specific cell
markers as follows: hematopoetic stem cells (HSCs):
Sca1+cKit+CD31−; mesenchymal stem cells (MSCs):
Sca1+CD105+CD31−; and endothelial progenitor cells
(EPCs): Sca1+ckit+CD31+ [18].
Assessment of stem cells in peripheral blood and kidney
To identify and evaluate stem cells in renal tissue and
blood, we employed a flow cytometry-based assay which
is well-established in our lab [18]. Briefly, for renal stem
cells, kidney samples were sieved through a cell strainer
(BD Biosciences, San Diego, CA) followed by centrifuga-
tion (1500 rpm, 10 min) to prepare single-cell suspen-
sions. For blood, samples of whole blood were treated
with reagents and stained with fluorochrome-conjugated
antibodies of interest based on the manufacturers’ in-
structions. Antibodies against Sca1, cKit, CD105, CD73,
CD31 (markers of murine stem cells), and caspase 3 (for
apoptosis) were obtained from BD Biosciences (San
Diego, CA). Phenotypic analyses of stem cells were per-
formed as described previously [19, 20]. Briefly, cells
were run through a four-color flow cytometer (FACS
Calibur, BD Biosciences, San Diego, CA), and data were
collected using CellQuest software. Samples were
double-stained with control IgG and cell markers and
were used to assess any spillover signal of fluoro-
chromes; proper compensation was set to ensure the
median fluorescence intensities of negative and positive
cells were identical and were both gated populations.
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Gating was used to exclude dead cells and debris using
forward and side scatterplots. In each analysis, 100,000
total events were collected. As a gating strategy, for each
sample, isotype-matched controls were analyzed to set
the appropriate gates. For each marker, samples were an-
alyzed in duplicate measurements. To minimize false-
positive events, the number of double-positive events
detected with the isotype controls was subtracted from
the number of double-positive cells stained with corre-
sponding antibodies (not isotype control), respectively.
Cells expressing a specific marker were reported as a
percentage of the number of gated events.
Cytospin technique and immunofluorescence staining
To maximize the yield of cells from the specimen, cytos-
pin technique was used as described previously [21].
Briefly, sorted cells per sample chamber (~20,000 cells)
were centrifuged (700 rpm, 5 min), air-dried, fixed in
10 % formalin, and washed twice in PBS. All subsequent
procedures were carried out at room temperature (RT).
Endogenous peroxidase activity was blocked with hydro-
gen peroxide (1:10 w/PBS, 10 min). All slides were
washed three times for 5 min at room temperature and
then incubated in blocking buffer (20 % normal donkey
serum, 1 % BSA, 0.02 % NaN3, 1× PBS) for 45–60 min.
Following treatment with the primary antibodies over-
night at 4 °C, preparations were then washed three times
with Tris-buffered saline for 5 min each time. All slides
were then incubated with the secondary fluorescence-
labeled antibody (all secondary Abs were purchased
from Jackson Immunoresearch Laboratories, West
Grove, PA) for 1 h in the dark at room temperature,
washed twice in Tris-buffered saline for 5 min each time
in the dark, and then counterstained using 4′,6-diami-
dino-2-phenylindole (DAPI) nuclear staining, mounted,
and were subjected to microscopic examination.
Results
Figure 1 shows percent of HSCs, MSCs, and EPCs
(expressed as of total circulating cells in peripheral
blood), using specific markers as described in the
“Methods” section, in the peripheral blood of experi-
mental groups. Although each stem cell subset was re-
duced in db/db mice compared to the db/m group, the
difference between the two groups was significant for
HSCs. On the other hand, Fig. 2 shows that cell prepara-
tions from kidneys of db/db mice have significant reduc-
tion in HSCs, MSCs, and EPCs compared to kidney cell
preparations of db/m mice, and the reduction in HSC in
db/db mice was even greater compared to that in per-
ipheral blood (Fig. 1).
We conjectured that increased apoptosis likely con-
tributes to reduction in stem cell subsets in cell prepara-
tions from kidneys of db/db mice compared to those of
their lean db/m controls. As shown in Fig. 3, indeed, db/
db mice displayed significant increase in apoptotic cell
death in kidney stem cell subsets compared to db/m
controls. To provide further support for our working hy-
pothesis that the diabetic milieu increases susceptibility
of stem cells to apoptosis, cytospin preparations of kid-
ney cells were subjected to immunofluorescent staining
for caspase 3 while DAPI was used as a nuclear marker;
these studies were carried out in conjunction with the
use of specific markers for each subset of stem cells.
While there was no discernable apoptotic foci for the
db/m control group (Fig. 4), stem cell subsets of db/db
kidneys showed marked immunofluorescent staining for
caspase 3 and merged images further confirm prominent
apoptosis of stem cell subsets of db/db kidneys (Fig. 5).
Discussion
The present study shows reductions in subsets of stem
cells in peripheral blood and renal cell preparations of
db/db mice, a model of type 2 diabetic nephropathy. We
further show increased apoptosis of HSCs, MSCs, and
EPCs in cell preparations from kidneys of db/db
Fig. 1 Bar graphs show levels of HSCs (Sca1+cKit+CD31−), MSCs
(Sca1+CD105+CD31−), and EPCs (Sca1+ckit+CD31+) in peripheral
blood of db/db and db/m mice. *p < 0.05 compared to the
db/m group
Fig. 2 Bar graphs show kidney cells prepared from db/db mice
display reduced levels of HSC, MSC, and EPC compared to their db/m
controls. *p < 0.05 compared to the db/m group
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compared to db/m mice. Collectively, the results suggest
that the diabetic milieu exerts detrimental effects on sur-
vivability of stem cell subsets in this animal model.
Given that stem cells are pivotal players in tissue repair
and regeneration following injury, reduction in their
numbers (and/or function) impairs the ability of the or-
ganism to cope with injury thereby contributing to pro-
gressive worsening of renal architecture and dysfunction.
Diabetes is the most common cause of ESRD [2].
Thus, there is an intense interest in slowing/halting the
progression of kidney disease and even promoting re-
gression of renal lesions and associated kidney dysfunc-
tion. Indeed, remission of the disease and regression of
renal lesions can occur in experimental animals and
human subjects; regression of glomerular structural
changes is associated with remodeling of the glomerular
architecture [14]. In specific circumstances, renal injur-
ies can at least partially heal and integrity as well as
functionality of the injured portion of the nephron be re-
stored [22–24]. Collectively, these observations indicate
that regeneration can occur to some extent in animals and
humans. Indeed, the kidney contains a stem/progenitor
cell system, defined as the “renopoietic system” dedicated
to renal epithelial cell replacement [22]. Further,
mobilization of endogenous stem cell reservoir (e.g.,
bone marrow) and exogenous delivery of stem cell regi-
mens constitute promising venues of addressing dia-
betic complications such as nephropathy. Importantly,
however, this approach must be combined with treat-
ment modalities aimed at achieving strict control of
metabolic abnormalities of the disease given the detri-
mental impact of hyperglycemia on stem cell number
and function. This contention is supported by a recent
study which investigated the impact of hyperglycemic
stress on kidney stem cells which were isolated from the
renal papilla showing expression of MSC markers (e.g.,
N-cadherin, nestin, CD133, CD29, CD90, and CD73)
[25]. When these cells were co-cultured with hypoxia-
injured renal tubular epithelial cells, they expressed
CK18, a marker of mature epithelial cells thereby sug-
gesting that kidney stem cells can differentiate into
renal tubular epithelial cells. Importantly, however, cul-
turing kidney stem cells in a high glucose environment
impaired their differentiation ability and tolerance to
hypoxia. Authors suggest that hyperglycemia compro-
mises the reparative ability of kidney stem cells and
could result in decreased ability to recover from injury.
The importance of strict metabolic control is also
clearly supported by observations that regression of
renal lesions in diabetic subjects, following pancreatic
transplantation, requires achievement of at least 5 years
of normoglycemia [24].
Fig. 3 Bar graphs show increased apoptotic HSCs, MSCs, and EPCs
in cell preparations obtained for kidneys of db/db than db/m mice.
*p < 0.05 compared to the db/m group
Fig. 4 Panels show immunofluorescent images of stem cell subsets for caspase 3 and DAPI and their merged images, for db/m mice
Baban et al. The EPMA Journal  (2016) 7:21 Page 4 of 7
Our observation of reduction in stem cell subsets in
the peripheral blood of db/db mice is consistent with
other reports indicating that EPCs are reduced in the
blood of patients with type 2 diabetes compared to their
controls, independent of concomitant risk factors [26].
The reduction in EPCs and associated decreased repara-
tive capacity, in response to endothelial injury, are be-
lieved to contribute to a higher risk for cardiovascular
disease associated with diabetes mellitus. Consequently,
the reduction in EPCs is an important pathogenic factor
contributing to microangiopathy which is intimately
linked with diabetic complications including nephropa-
thy. Aside from a reduced number, EPCs also show
impaired functional features including adhesion, prolifer-
ation, and tubulogenesis. Thus, both reduced number
and impaired function of EPCs compromise the ability
to counter diabetes/hyperglycemia-induced injury [26].
Aside from EPCs, (bone marrow-derived) MSCs play
important roles, largely via paracrine mechanism, in re-
pair and regeneration of damaged tissues. Importantly,
however, bone marrow-derived MSCs of streptozotocin-
induced diabetic rats display impaired proliferation,
paracrine release of various factors (e.g., vascular endo-
thelial growth factor), anti-apoptosis, and myogenic dif-
ferentiation in transplanted tissues [11]. In addition,
impairment of bone marrow-derived HSCs is also a fea-
ture of diabetes thereby leading to endothelial progenitor
cell dysfunction and reduced neovascularization follow-
ing ischemic insult to the tissue [13].
As alluded earlier, decreased proliferation is believed
to contribute to reduced number of stem cells in dia-
betes mellitus. We now provide evidence that increased
apoptosis is also an important contributing factor to de-
creased number of stem cells in this condition. This is
consistent with our recent study indicating marked in-
crease in apoptotic/necrotic cell death in whole kidney
cell preparations of db/db than db/m mice, an effect
associated with increased GADD153, a marker of in-
creased endoplasmic reticulum (ER) stress response [10].
Aside from ER stress response, hyperglycemia upregu-
lates several pathways (e.g., protein kinase C, polyol
pathway, advanced glycation end products, and hexosa-
mine) which along with mitochondrial dysfunction cause
increased oxidative stress [25]. In turn, oxidative stress
regulates a complex web of signaling pathways which,
among other effects, determine cell fate. For example,
oxidative stress causes activation of a number of pro-
apoptotic kinase signaling intermediates; these include
several isoforms of protein kinase C, apoptosis signal-
regulating kinase 1, c-Jun-N-terminal kinase and cas-
pase, among others [27]. Thus, hyperglycemia-induced
upregulation of pro-apoptotic pathways likely underlies
increased cell death not only for the whole kidney as we
have shown previously [10] but also in stem cell subsets
in the present study in the db/db mice. However, there
are very likely to be individual differences in the degree
of hyperglycemia-induced upregulation in apoptosis
among diabetic patients. This is evidenced by the fact
that nephropathy is seen in 25 to 40 % of the diabetics
[1]—implying 60 to 75 % have been able to avoid it, at
least for some time. Quantitative and qualitative varia-
tions abound in biology and medicine, as do all complex
adaptive systems. The increase in apoptosis may be an
adaptive response to ER stress in some individuals. For
these patients, the sum total cost is less to have pro-
grammed cell death and avoid spilling DAMP (damage-
associated molecular pattern) which can further stimulate
the inflammatory responses that are already elevated.
Fig. 5 Panels show immunofluorescent images of stem cell subsets for caspase 3 and DAPI, and their merged images, for db/db mice
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What is needed is for us to build and iteratively improve
multi-variate high-dimensional computational models
based on experimental and clinical data such as provided
in this report. It is only with this mechanistic approach
that future therapies can be individualized based on serum
marker profiles, deep understanding, and logic, rather
than experience and hope.
Outlook
The paradigm shift in health care from reactive to per-
spective medicine is crystallized in the concept of pre-
dictive, preventive, and personalized medicine (PPPM)
[28, 29]. At the heart of PPPM is the ability to predict
individuals who are at risk of developing a disease and/
or its complications. With respect to type 2 diabetes, it
is increasingly apparent that not all patients progress to
develop end-stage renal disease, further emphasizing the
need for accurate prediction of those at risk of develop-
ing this devastating complication. Nonetheless, it is
abundantly clear that the diabetic milieu is detrimental
to repair and reparative mechanisms that maintain organ
homeostasis. Utilizing an animal model of type 2 dia-
betic nephropathy, we now show that the decline in the
peripheral blood and renal tissue levels of stem cell sub-
sets is associated with increased apoptosis. This observa-
tion is important for several reasons. First, since
impairment of stem cells is likely to precede renal injury,
early assessment and monitoring of peripheral blood
stem cells could serve as a useful tool for predicting in-
dividuals who may progress to end-stage renal disease.
Second, strict metabolic control could not only preserve
the endogenous pool of stem cells and their repair/re-
generative capacity but also improve the outcome of
stem cell-based therapies. Third, although strict meta-
bolic control is a noble objective, it is often difficult to
achieve for many patients which not only jeopardizes
mobilization of their endogenous repair and regenerative
capacity, as it relates to function of stem cells, but also is
a major impediment to harnessing the full therapeutic
potential of stem cell-based therapies. Interestingly,
however, it is increasingly clear that the beneficial effects
of stem cells are largely related to their release of a
whole host of soluble factors and their subsequent para-
crine effects rather than to their transdifferentiation [30,
31]. Thus, it is plausible that patient’s own peripheral
blood-derived stem cells could be procured and sub-
jected to in vitro expansion followed by preparation of
their lysates/extracts for subsequent administration,
thereby bringing “true” meaning to individualized treat-
ment approach. To that end, further pre-clinical and
clinical research is essential to establish the value of this
approach and determine whether it can circumvent
impediments to stem cell-based therapy such as their
survivability in the diabetic milieu and their homing to
intended organ(s), among others [32–34]. This approach
could complement other innovative or existing ap-
proaches to treatment of diabetes mellitus and its com-
plications [35].
Conclusion
This study shows that apoptosis of stem cells likely con-
tributes to development of nephropathy in diabetes
mellitus.
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